Randomised controlled trials comparing lowv. high-fat diets on cardiometabolic risk factors in people with overweight or obesity have shown inconsistent results, which may be due to the mixed metabolic status of people with excess adiposity. The role of dietary fat manipulation in modifying cardiometabolic indicators in people with overweight or obese without metabolic disturbance is unclear. Thus, meta-analysis was conducted to compare lowv. high-fat diets on cardiometabolic indicators in people who are overweight or obese without metabolic disturbance in the present study. Databases were searched until October 2016. The pooled effects of outcomes with heterogeneity were calculated with a random-effects model, heterogeneities were analysed by subgroup and meta-regression. As a result, twenty studies with 2106 participants were included in the meta-analysis. Total cholesterol and LDL-cholesterol levels were lower following low-fat diets compared with high-fat diets: weighted mean difference (WMD) was −7·05 mg/dl (−0·18 mmol/l; 95 % CI −11·30, −2·80; P = 0·001) and −4·41 mg/dl (−0·11 mmol/l; 95 % CI −7·81, −1·00; P = 0·011), respectively. Conversely, significant higher level of TAG (WMD: 11·68 mg/dl (0·13 mmol/l), 95 % CI 5·90, 17·45; P < 0·001) and lower level of HDL-cholesterol (WMD: −2·57 mg/dl (−0·07 mmol/l); 95 % CI −3·85, −1·28; P < 0·001) were found following low-fat diets compared with high-fat diets. In conclusion, dietary fat manipulation has a significant influence on blood lipid levels in people with overweight or obesity without metabolic disturbances.
Excessive body weight (BW) is a global public health issue. According to the WHO's investigation in 2015, worldwide obesity has more than doubled since 1980 (1) . Excess adiposity is associated with chronic diseases through various metabolic pathways and their complications such as elevated blood pressure, elevated plasma glucose and dyslipidaemia (2) (3) (4) . Traditional weight loss diets are usually low in fat to decrease overall daily energy intake and because of the favourable effects on blood lipids (5) . This traditional dogma is now contentious with several studies comparing low-fat with high-fat diet showing variable results on BW and cardiometabolic indicators in people with overweight or obesity (6) (7) (8) (9) . Notably two systematic reviews and meta-analyses (8, 9) have reported common findings that high-fat diets v. low-fat diets result in higher fasting plasma total cholesterol (TC) and LDL-cholesterol, but lower fasting plasma TAG and higher HDL-cholesterol. The effects on BW are less clear with one meta-analysis reporting that overall there is no difference when comparing low-fat v. high-fat diets, however when these diets were combined with energy restriction the difference was greater with the high-fat intervention (9) . Whereas in a more recent meta-analysis there was a greater change in BW after high-fat diets compared with low-fat diets (8) . As there appears to be elevated LDL-cholesterol with consumption of high-fat diets, caution has ensued in recommending this dietary pattern in combination with overall energy restriction for facilitating weight loss.
Dietary fat may confer different effects on blood lipids in people with overweight or obesity depending on whether there is underlying metabolic disease or not. Excess adiposity is not always concomitant with metabolic complications or CVD. These people have been described as 'metabolically healthy obese' (MHO) (10) (11) (12) . MHO individuals are characterised by Abbreviations: BW, body weight; DBP, diastolic blood pressure; Hs-CRP, high-sensitivity C creative protein; MHO, metabolically healthy obese; MUO, metabolically unhealthy obese; RCT, randomised controlled trial; SBP, systolic blood pressure; TC, total cholesterol; WMD, weighted mean difference.
reduced cardiometabolic risk (relative to weight-matched individuals with metabolic disturbances), as reflected by preserved insulin sensitivity, a reduced inflammatory status and a normal circulating lipid profile (13) . Importantly, recent studies estimate that the prevalence of this phenotype may be as high as 30 % of the obese population (14, 15) . If excess adiposity is sustained a metabolically unhealthy phenotype may develop (16) . This is an important sub-clinical population to study to assist with development of strategies which aim to prevent the onset of metabolic complications. A growing number of studies show that in addition to lifestyle and dietary differences, there are also differences in the expression of genes linked to CVD progression in this sub-clinical population, compared with those who have excess adiposity in combination with metabolic disturbances (17) (18) (19) (20) . With the increased number of randomised controlled trials (RCT) that have compared a low-fat diet with a high-fat diet in metabolically healthy people with overweight or obesity, a systematic review and meta-analysis to summarise the impact of these diets on cardiometabolic risk factors is now warranted. This is important for developing best-practice dietary guidelines, particularly for MHO populations.
Methods

Literature search
All of the processes of article searching were conducted by two investigators independently. Literature search was limited to RCT without any restriction on language or calendar date. The databases MEDLINE, EMBASE and the Cochrane Trial Register were searched through to October 2016. The structured search strategies used the following format of terms: (low fat diet OR low fat diets OR reduced fat) AND (obese OR obesity OR overweight OR weight loss). This combination of search terms were selected to ensure that all relevant studies were identified through and screened for eligibility. The reference lists of retrieved articles were also checked for additional publications. This systematic review was conducted in adherence to the standards of the Preferred Reporting Items for Systematic Review and Meta-Analysis statement (21) .
Eligibility criteria
Studies were reviewed by title and abstract first and then the fulltext for the final eligibility of a study. Only studies that met all of the following criterions were included: (i) RCT; (ii) the BMI of the participants ≥25 kg/m 2 ; (iii) the intervention should be a low-fat diet (<30 % of total energy consumption) compared with a highfat diet (≥30 % of total energy consumption); (iv) participants are metabolically healthy according to Wildman et al. (22) : where less than two of the following criterions should be found: blood pressure ≥ 130/85 mmHg; TAG ≥ 1·7 mmol/l; HDL-cholesterol for men <1·03 mmol/l, for women <1·30 mmol/l; glucose ≥ 5·6 mmol/l; homoeostasis model assessment-insulin resistance > 4·27 (i.e. 90th percentile); high-sensitivity C-reactive protein (Hs-CRP) > 7·89 mg/dl (i.e. 90th percentile); (v) having at least one of the outcomes (BW, systolic blood pressure (SBP), diastolic blood pressure (DBP), LDL-cholesterol, HDL-cholesterol, TC, TAG, insulin, glucose, leptin, total adiponectin and Hs-CRP) for assessment and report of post intervention mean or mean of two time point values with standard deviation (or basic data to calculate these parameters). Studies were excluded if the high-fat diet accounted for only 30 % of the total energy or if any of the participants were using drugs that could influence the result of interest (lipid modification drugs, hormone drugs, slimming drugs, etc.). Diets that replaced fat with artificial fat were excluded. If there were studies published as updates, only the study that had the most outcomes of interest was included.
Data extraction
For all included studies, the following data were extracted: the first author's name, date of publication, country where participants reside, follow-up period, study design, drop-out rate, total number of participants, female percentage and post intervention mean values or differences in mean of two time point values with corresponding standard deviation. In case of more than one low-fat group or high-fat group within a single study design, data were combined according to the methods recommended by the Cochrane collaboration (23) . If standard deviation was not provided, it was calculated from standard error of mean or 95 % CI. Extracted data were turned to unified units. For TC, LDL-cholesterol and HDL-cholesterol, 1 mmol/l was converted to 38·61 mg/dl; for TAG, 1 mmol/l was converted to 88·50 mg/ dl; for plasma glucose, 1 mmol/l was converted to 18 mg/dl.
Quality assessment and risk of bias
Methodology quality of the included studies were assessed by both the JADAD score and risk of bias assessment. Two investigators conducted the assessment independently. The modified JADAD score (seven-point) was used according to randomisation (randomisation = 1 point, random number generated by computer or similar methods = an additional 1 point) , concealment of allocation (random number table or similar methods = 1 point, the allocation scheme is controlled by centre or pharmacy, or using of opaque envelopes or other methods that be secret to clinicians and subjects of the allocation methods = an additional 1 point), double-blinding (double-blind = 1 point, use of a placebo = additional 1 point), withdrawals and dropouts (numbers and reasons for drop-out are stated = 1 point). Final scores of 0-3 points were considered to be of low quality and 4-7 points as high quality (4, 24) .
Risk of bias of the included studies were assessed using the Cochrane Collaboration's risk of bias tool following six domains: (i) selection bias (random sequence generation allocation concealment); (ii) performance bias (blinding of participants and personnel); (iii) detection bias (blinding of outcome assessment); (iv) attrition bias (incomplete outcome date); (v) reporting bias (selective reporting); (vi) other bias (25) . Data were analysed using Review Manager 5.3 software to give an overview of the risk of bias within the included studies against theses six domains.
Statistical analysis
Meta-analysis was performed for all outcomes to determine the pooled effect of the intervention. A random-effects model described by DerSimonian & Laird (26) was used to estimate weighted mean differences (WMD) with 95 % CI. Heterogeneity of the trial results were tested by Q test and I 2 parameter. I 2 ≤ 25 % was considered to be low heterogeneity, 25 % < I 2 ≤ 50 % moderate heterogeneity, whereas I 2 ≥ 75 % was considered to be high heterogeneity (27) . In order to find out the source of heterogeneity, subgroup analysis was carried out for outcomes that had a moderate or high heterogeneity focused on the following covariates : the percentage of female (>80 or ≤ 80 %); fat percentage of high-fat diet (≥45 or <45 %); carbohydrate percentage of lowfat diet (>55 or ≤ 55 %); duration (<3, 3-6 or >6 months); energy restriction (both restricted or low fat only or high fat only or no); high-fat diet type (low-carbohydrate diet or other high-fat diet types); drop-out rate (>20 or ≤ 20 %); Continent (North America, Europe or others); the JADAD score (≥4 or <4). Univariate metaregression was also conducted where there were more than 10 studies including the dependent variables of interest. Most of the cut points of subgroups were chosen by median. Sensitivity analysis was applied to assess whether one single study influenced the results excessively. Begg's test and Egger's test were performed and the symmetry of the funnel plots assessed to examine potential publication bias. All of the analyses were conducted using Stata/SE 12.0 (add publisher/manufacture details). Twosided P < 0·05 was considered to be statistically significant.
Results
Literature search
A total of 4877 articles were retrieved: 989 from Medline, 2324 from Embase and 1564 from the Cochrane trial register. Following first and second pass screening, twenty studies were eligible for inclusion, resulting in 2106 participants for the metaanalysis (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . Details for the screening steps and reasons for exclusion are shown in Fig. 1 .
Characteristics of studies included
Included studies were published between 1993 and 2014 and intervention duration ranged from 6 weeks to 2 years. Most of the trials were conducted in USA (n 12). All participants were adults aged ≥ 18 years old and BMI ≥ 25 kg/m 2 . Five of the studies were conducted exclusively on women. The proportion of energy from fat in low-fat diet ranged from 12 to 30 %, whereas carbohydrate ranged from 52 to 65 %. There were twelve trials with restricted energy intake in both diets. The number of included studies reporting on outcomes of interest were as follows: BW (n 14), SBP and DBP (n 10), plasma LDLcholesterol (n 18), HDL-cholesterol (n 18), TC (n 16), TAG (n 19), plasma insulin (n 14), plasma glucose (n 14), leptin (n 5), adiponectin (n 3) and Hs-CRP (n 7) respectively. Nine of the included studies scored ≥ 4 of the JADAD score, no study scored less than 2 points (Table 1) . No obviously high risk of bias was found (Fig. 2 ).
The effects of low-fat diet compared with high-fat diet on cardiometabolic indicators
A more pronounced reduction of TC and LDL-cholesterol was found after following a low-fat diet compared with high-fat diets: WMD −7·05 mg/dl (−0·18 mmol/l; 95 % CI 11·30, −2·80; P = 0·001) and −4·41 mg/dl (−0·11 mmol/l; 95 % CI −7·81, −1·00; P = 0·011), respectively. Conversely, HDL-cholesterol was lower and TAG higher after the low-fat diet compared with high-fat diets: WMD were −2·57 mg/dl (−0·07 mmol/l; 95 % CI 3·85, −1·28; P < 0·001) and 11·68 mg/dl (0·13 mmol/l; 95 % CI 5·90, 17·45; P < 0·001), respectively. Low-fat diet was also associated with higher DBP compared with high-fat diets, the WMD was 2·18 mm Hg (95 % CI 0·74, 3·62; P = 0·003). There appeared to be no significant difference between low-fat and high-fat diets on: BW (P = 0·548), SBP (P = 0·114), plasma glucose (P = 0·347), plasma insulin (P = 0·106), leptin (P = 0·679), Hs-CRP (P = 0·623) or adiponectin (P = 0·100) (Table 2) ( Fig. 3 ). For the studies that measured TC, TAG, HDL-cholesterol, LDL-cholesterol, subgroup analyses found that the following factors confounded the effects of low-fat diet compared with high-fat diet: drop-out rate > 20 % and the JADAD score <4, P values of these four indicators remained significant only when drop-out rate <20 % and the JADAD score > 4. The proportion of dietary fat on the high-fat diet was also a source of heterogeneity and for studies where dietary fat ≥ 45 %, there was a greater change for the size effects of TAG (WMD: 35·26 mg/dl; 95 % CI 20·15, 50·36; P < 0·001) and BW (WMD: 3·98 kg; 95 % CI 2·25, 5·72; P < 0·001) on the low-fat diet compared with high-fat diet. Compared with high-fat diet, the reduction of LDL-cholesterol was more marked when carbohydrate percentage ≤ 55 % in low-fat diet (WMD: −6·87 mg/dl; 95 % CI −11·20, −2·54; P = 0·002). When female percentage ≤ 80 %, fasting plasma glucose was greater after low-fat diet compared with high-fat diet (P = 0·002). However, most of the heterogeneity were only partly explained by subgroups (Tables 3 and 4 ).
Subgroup and meta-regression analysis
Sensitivity analysis and publication bias
Sensitivity analysis showed there was no apparent difference for the pooled estimate of the WMD for the effects of low-fat diet on BW, HDL-cholesterol, TC, TAG, SBP, DBP, or LDLcholesterol after any one study was removed (online Supplementary Fig. S1 -S12). The results for Begg's rank correlation test and Egger's linear regression test indicated that there were no obvious publishing bias detected in the metaanalysis of BW, TC, TAG, SBP, DBP, LDL-cholesterol, plasma insulin, leptin, Hs-CRP and adiponectin. Publication bias may exist for HDL-cholesterol and plasma glucose according to Egger's linear regression test (P < 0·001), however, it was not evident from the Begg's rank correlation test (P = 0·820, P = 0·477) ( Table 5 and online Supplementary Fig. S13-S36 ).
After further analysed by the trim and fill method, there were no articles indicated to be trimmed, which suggests little evidence for publication bias.
Discussion
To our knowledge, this is the first meta-analysis to systematically compare the effects of low-fat diet with high-fat diet in people who are metabolically healthy but are overweight or obese. This is important for contributing to understanding what factors may be involved in the transition from a metabolically healthy profile to a metabolically unhealthy profile and consequently increase disease risk. Findings of this metaanalysis suggests that short-to medium-term (6 months-2 years) intake of low dietary fat compared with high dietary fat was associated with lower plasma TC and LDL-cholesterol. Conversely, low-fat diet was associated with a more unfavourable change in TAG, HDL-cholesterol and DBP compared with high-fat diet. There appeared to be little impact of the low-fat diet on other cardiometabolic risk factors compared with highfat diet including BW, SBP, plasma insulin, plasma glucose, leptin, adiponectin and Hs-CRP. These results should be explained cautiously.
Metabolic phenotype with excess adiposity
The results of this meta-analysis are consistent with that of Schwingshackl & Hoffmann's (9) , who compared low-fat diets with high-fat diets in overweight and obese populations without screening of metabolic status, and the results found low-fat diets were associated with lower TC and LDL-cholesterol levels, whereas high-fat diets were associated with lower TAG level and higher HDL-cholesterol level. However, WMD of all of the four blood lipid indicators were more remarkable in the present meta-analysis than Schwingshackl & Hoffmann's (9) , which suggests that overweight and obese populations with healthy metabolism have a more distinct reaction to dietary fat than those metabolically unhealthy people. 
Suppressing the conversion from metabolically healthy to metabolically unhealthy obesity
Epidemiological studies have shown that MHO populations are at a lower risk of some chronic diseases and lower all-cause mortality than metabolically unhealthy obese (MUO) (17, 48, 49) , it is therefore, meaningful to find methods to stop the transition from MHO to MUO. Soriguer et al. (50) have found that after a 6year's follow-up, about 37 % of the MHO population transformed to MUO, a recent longitudinal study also indicate that MHO is an intermediate stage to MUO (51) . A prospective study reported that a healthy lifestyle helps to maintain a favourable cardiometabolic profile and thus counterbalance the risk of transition from MHO to MUO (20) . According to these results, macronutrient composition of the diet, including the amount and the type of dietary fat may play an important role in maintaining metabolic healthy status in people with excess adiposity. However, according to the results of the present meta-analysis, it is unclear what role dietary fat may play in the transition from MHO to MUO.
Dietary fat and body weight
In this meta-analysis that included participants with excess adiposity and who were metabolically healthy, significant difference between low-fat diets and high-fat diets on weight loss was not found. Besides, no remarkable differences between low-fat diets and high-fat diets were found for either leptin or adiponectin in the present study ( Table 2 ). Both leptin and adiponectin are well known to be inversely correlated with BW (52, 53) , leptin represses food intake and increases food expenditure to regulate BW (54) (55) (56) (57) . These results are consistent with pooled data from RCT, which showed that low-fat diet have little effect on weight loss during long-term intervention of more than 12 months (58) compared with high-fat diet. However, another meta-analysis concluded RCT and cohort studies found that diets low in total fat were associated with lower relative BW (59) compared with high-fat diets. These disparate results may be because of the different type of dietary fat and different duration of intervention. As most of the experimental diets were energy restricted, both the low-fat diets and high-fat diets should be effective for weight loss, however, the potential benefits of the high-fat diet may because of the greater satiety. Besides, most of the high-fat diets were also low carbohydrate diets, low carbohydrate diets have been reported to be good for weight loss (60) (61) (62) . So further studies that aim to compare the effects of low-fat diet with high-fat diet on weight loss should control the percentage of carbohydrate between the two diets.
Dietary fat and CVD
The proportion of dietary fat in the low-fat diets in this review is consistent with the latest American Dietary Guidelines recommendation on fat intake. In this meta-analysis, high-fat diets Selective reporting (reporting bias) Fig. 2 . Summary of risk of bias within the included studies across the six domains: selection bias; performance bias; detection bias; attrition bias; reporting bias; and other bias (22) . The proportion of included studies with each judgement: , low risk of bias; , unclear risk of bias; , high risk of bias. were found to be favourable for TAG (P < 0·001) and HDLcholesterol (P <0·001), and these results are also consistent with the studies including metabolically heterogeneous groups of participants (63) (64) (65) . In patients with type 2 diabetes, high-fat diet was also associated with lower TAG level and higher HDL-cholesterol level compared with low-fat diet (66) . As TAG and HDL-cholesterol levels are important indices for CVD risk, each 10 mg/dl (0·26 mmol/l) increase of HDL-cholesterol is associated with a decreased CHD risk of 29 % (67) . The present metaanalysis found that high-fat diets can bring an average increase 
WMD, weighted mean differences. * P for effect size; it was calculated with a random effect model with weighted mean difference. † P for univariate meta-regression analysis. WMD was used as the dependent variables and the SE (WMD) as variable name. ‡ JADAD score were graded by modified JADAD score method. * P for effect size; it was calculated with a random effect model with weighted mean difference· † P for meta-regression analysis. ‡ JADAD score were graded by modified JADAD score method.
of HDL-cholesterol concentration of 2·57 mg/dl (0·066 mmol/l) compared with a low-fat diet which means a relative risk reduction for CVD of 7·45 %. The improvement in TAG after following a high-fat diet may be linked to an increased intake of PUFA which have been demonstrated to be favourable for reducing TAG and VLDLcholesterol as well as increasing HDL-cholesterol. For example, EPA can reduce serum levels of TAG by inhibiting the activity of fat synthetase and reducing fatty acids for synthesising TAG. Besides, n-6 PUFA can inhibit the expression of stearyl coenzyme A desaturation enzyme in adipocytes, which is also an important enzyme in the synthesis of TAG.
Interestingly, subgroup analysis by geographical location in the present meta-analysis found greater effect sizes for low-fat diets compared with high-fat diets on serum levels of TC and TAG of trials conducted in North America than in Europe; and for LDL-cholesterol and HDL-cholesterol, those trials conducted in Europe lost statistical significance. Dietary sources of fat often vary between Europe and North America which may further hint towards an effect of fat type as a source of heterogeneity. A limitation of this review is that most of the studies included in this meta-analysis did not analyse the type of fat. Future studies should consider the effect of types of dietary fat on cardiometabolic changes in dietary intervention studies.
Strengths and weaknesses of the article
The strengths of this meta-analysis and systematic review is the large sample size ,with little publication bias evident, which permitted analysis using meta-regression to investigate the potential sources of heterogeneity. The limitations of the present study include: the lack of detailed information on the type of dietary fat which prohibited the analysis of the mechanisms between fat-type and cardiometabolic risk factors; the lack information on blinding within studies which increases the risk of bias and similarly the bias introduced into several studies by the high (>20 %) attrition rate; and the heterogeneity can only be partly explained through the meta-regression performed indicating other unknown factors account for the findings for some parameters.
Conclusion
This meta-analysis found that people who are overweight/obese but metabolically healthy, exhibit some metabolic changes after dietary fat manipulation. This is mostly characterised by an overall decrease in plasma TC, LDL-cholesterol, HDL-cholesterol and an increase in TAG following low-fat diets compared with high-fat diets. Future studies are needed to focus on the influences of different types of fat. More high-quality RCT for low-fat diet v. high-fat diet on metabolically healthy overweight and obese are warranted to inform dietary guidelines. Hs-CRP, high-sensitivity C-reactive protein.
